EP Patent

EP4014971A1 — C-met modulator pharmaceutical compositions

Assigned to Exelixis Inc · Expires 2022-06-22 · 4y expired

What this patent protects

Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.

USPTO Abstract

Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: EP4014971A1
Jurisdiction: EP
Classification: —
Expires: 2022-06-22
Drug substance claim: No
Drug product claim: No
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.